Bispecific T-Cell Engagers Market Report 2026

The bispecific t-cell engagers market size has grown exponentially in recent years. It will grow from $1.6 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to limited efficacy of conventional cancer therapies, rising incidence of hematologic malignancies, growing understanding of immune-oncology mechanisms, early regulatory approvals for bispecific antibodies, increasing investment in oncology research.

The bispecific t-cell engagers market size is expected to see exponential growth in the next few years. It will grow to $4.18 billion in 2030 at a compound annual growth rate (CAGR) of 21.2%. The growth in the forecast period can be attributed to expansion of solid tumor indications, advancements in antibody engineering platforms, growing clinical success rates of t-cell engagers, increasing healthcare expenditure on cancer immunotherapy, rising strategic partnerships and licensing deals. Major trends in the forecast period include increasing adoption of bispecific t-cell engagers in hematologic malignancies, rising focus on targeted immunotherapy and precision oncology, expansion of clinical trials for solid tumor applications, growing investment in antibody engineering and novel formats, rising collaborations between biotech firms and research institutes.

The increasing incidence of cancer is expected to drive the growth of the bispecific T-cell engagers market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade and damage surrounding tissues. The rising incidence of cancer is primarily attributed to aging populations and unhealthy lifestyle habits, as advancing age leads to the accumulation of genetic mutations over time, while behaviors such as smoking, poor dietary choices, and physical inactivity increase cancer risk. Bispecific T-cell engagers aid in cancer treatment by simultaneously binding to T cells and tumor cells, effectively linking the immune system to cancer targets. This mechanism activates a patient’s own T cells to recognize, attack, and destroy malignant cells with high specificity. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately 20 million new cancer cases were diagnosed in 2022, and this number is projected to increase by 77% to more than 35 million cases by 2050. Therefore, the rising incidence of cancer is driving the growth of the bispecific T-cell engagers market.

Major companies operating in the bispecific T-cell engagers market are concentrating on advanced strategies, such as enhancing cytolytic synapse formation, to improve targeted tumor cell destruction. Cytolytic synapse formation refers to the process in which a T cell establishes a specialized contact with a cancer cell, allowing the delivery of lethal signals that result in tumor cell death. For instance, in May 2024, Amgen Inc., a US-based biopharmaceutical company, launched IMDELLTRA (tarlatamab-dlle), the first and only therapy approved by the US Food and Drug Administration (FDA) that targets DLL3 using a bispecific T-cell engager for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This therapy activates patients’ T cells to attack DLL3-expressing tumor cells, offering a novel immunotherapy option for individuals whose disease has progressed following platinum-based chemotherapy.

In March 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Harpoon Therapeutics Inc. for an undisclosed amount. Through this acquisition, Merck aims to enhance and diversify its oncology pipeline by advancing innovative bispecific T-cell engager therapies to expand treatment options for patients with advanced cancers. Harpoon Therapeutics Inc. is a US-based clinical-stage immuno-oncology company specializing in the development of bispecific gamma-delta T-cell engager therapies for cancer treatment.

Major companies operating in the bispecific t-cell engagers market are Pfizer Incorporated, Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Incorporated, Sanofi S.A., Amgen Incorporated, Regeneron Pharmaceuticals Incorporated, Ipsen S.A., Genmab A/S, Evotec SE, Akeso Inc., Immunocore Holdings Public Limited Company, MacroGenics Incorporated, Zymeworks Inc., Zenas BioPharma Limited, Candid Therapeutics Inc., BPS Bioscience Inc., Alloy Therapeutics Inc., AP Biosciences Inc., Medigene AG.

North America was the largest region in the bispecific T-cell engagers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bispecific t-cell engagers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bispecific t-cell engagers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the bispecific t-cell engagers market by increasing costs associated with imported biologics, antibody production materials, and specialized manufacturing equipment. Hospitals and specialty clinics in regions such as North America and Europe, which depend on global supply chains, are most affected. These cost pressures may slow adoption and clinical expansion. However, tariffs have also encouraged localized biologics manufacturing, increased investment in domestic production capabilities, and innovation in cost-efficient antibody development.

The bispecific t-cell engagers market research report is one of a series of new reports that provides bispecific t-cell engagers market statistics, including bispecific t-cell engagers industry global market size, regional shares, competitors with a bispecific t-cell engagers market share, detailed bispecific t-cell engagers market segments, market trends and opportunities, and any further data you may need to thrive in the bispecific t-cell engagers industry. This bispecific t-cell engagers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bispecific T-cell engagers are a class of engineered antibodies designed to bind simultaneously to T cells and cancer cells. By linking these two cell types, they redirect the immune system to more effectively identify and eliminate tumor cells. This targeted mode of action makes them a promising immunotherapy option, particularly for the treatment of hematologic malignancies and certain solid tumors.

The main product types of bispecific T-cell engagers include monoclonal antibodies, bispecific antibodies, and others. Monoclonal antibodies are laboratory-engineered proteins developed to selectively bind to a single target antigen and are used in the treatment of conditions such as cancer, autoimmune diseases, and infections by inhibiting harmful molecules or tagging them for immune-mediated destruction. These products are applied in areas including hematologic malignancies, solid tumors, and others, and are utilized by various end users such as hospitals, specialty clinics, research institutes, and others.

The bispecific T-cell engagers market consists of sales of solitomab, ebentafusp, glofitamab, epcoritamab, and mosunetuzumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.